Usefulness of assisted procedures for arteriovenous fistula maturation without compromising access patency

Park, Hoon Suk; Lee, Youn Hee; Kim, Hyung Wook; Baik, Jun Hyun; Won, Yong Sung; Park, Cheol Whee; Kim, Young Ok; Yang, Chul Woo; Jin, Dong Chan

doi:10.1111/hdi.12499

Cited by 11 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Age has been described as an important factor influencing the AVF patency in several studies, [ 5 , 17 , 21 ] but, no significance was observed in our study. On the contrary, patients more than 65 years of age showed longer secondary patency, but this is not concluded with statistical significance in our study.…”

Section: Discussioncontrasting

confidence: 94%

“…To solve this problem, several reports suggest mapping, vascular access counseling as well as surgical ligation or embolization of accessory vein and PTA. [ 3 , 5 , 8 ]…”

Section: Discussionmentioning

confidence: 99%

“…To make these AVFs available, endovascular management, mostly percutaneous transluminal angioplasty (PTA) has been regarded as an effective technique. [ 5 – 7 ] Besides treating stenosis or occluded lesion with angioplasty, ligation or embolization for an accessory vein that hinders AVF growth is also considered. [ 5 , 8 , 9 ]…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Endovascular management in immature arteriovenous fistula for hemodialysis

et al. 2018

View full text Add to dashboard Cite

To evaluate the outcomes and prognostic factors of endovascular management in immature arteriovenous fistula (AVF) for hemodialysis.From April 2007 to September 2017, 54 patients (male:female = 31:23, mean age 65.63 years, range 33–90 years) who underwent endovascular management for the salvage of immature AVF were retrospectively reviewed. Clinical data, procedural details, and results were evaluated. Primary and secondary patency rates and factors influencing the patency were also analyzed.Technical and clinical success rates were 88.9% (48/54) and 85.2% (46/54), respectively. Mean primary and secondary patency was 42.10 (±8.85) and 91.5 (±14.77) months, respectively. Primary and secondary patency rates were 66% and 89% in 1 year, 66% and 78% in 2 years, and 51% and 78% in 3 years. In multivariate analysis, only brachiocephalic AVF and antegrade access procedures showed significantly shorter primary patency (HR 5.196; 95% CI (1.04–25.77); P = .044, HR 8.096; 95% CI (1.36–48.00); P = .021). There was no statistically significant factor associated with secondary patency in the multivariate study.Endovascular management in immature AVF is safe and effective to make the AVF available. Brachiocephalic AVF and antegrade access procedures are the factors influencing the patency in multivariate analysis.

show abstract

Section: Discussioncontrasting

confidence: 94%

“…To solve this problem, several reports suggest mapping, vascular access counseling as well as surgical ligation or embolization of accessory vein and PTA. [ 3 , 5 , 8 ]…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Endovascular management in immature arteriovenous fistula for hemodialysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…During the entire study period, the initial VAIVT success rate was 93.8%, similar to that reported by previous studies [19][20][21][22][23][24][25]. In addition, the 1-year patency rate was 39.7% (Fig.…”

Section: Initial Success and Primary Patency Ratessupporting

confidence: 87%

Patency with antiplatelet treatment after vascular access intervention therapy: a retrospective observational study

et al. 2018

View full text Add to dashboard Cite

Background: Vascular access (VA) intervention therapy (VAIVT) has been increasingly used for treating VA failure (VAF) in patients undergoing hemodialysis; however, clinical evidence demonstrating the efficacy of prevention of VAF after VAIVT is limited. Therefore, we aimed to assess characteristics of patients developing VAF after VAIVT and analyze risk factors for VAF after VAIVT. Methods: This retrospective study included 96 patients with VAF who underwent ultrasound-guided VAIVT by interventional nephrologists between January 2013

show abstract

“…Problems related to HD VA affect the survival rate of ESRD patients. Various techniques of endovascular therapy resulted in a breakthrough development in the treatment of HD VA [11–13]. However, the lesion of CV is much less responsive to endovascular therapy than that of a peripheral location.…”

Section: Treatmentmentioning

confidence: 99%

Central venous disease in hemodialysis patients

Park

Choi

Baik

2019

Kidney Res Clin Pract.

Self Cite

View full text Add to dashboard Cite

Central venous disease (CVD) is difficult to treat and often resistant to treatment. In CVD, hemodialysis vascular access should sometimes be abandoned, or in serious cases, the patient's life may be threatened. Therefore, prevention is ideal. However, as the prevalence of chronic kidney disease (CKD) has increased steadily with population aging, CKD patients with a peripherally inserted central catheter (PICC) are encountered frequently. PICCs can cause CVD, and the basilic vein, which is regarded as the important last option for native arteriovenous fistula (AVF) creation in end-stage renal disease (ESRD) patients, is destroyed frequently after its use as the entry site of PICC. The most well-established risk factors for CVD are a history of central venous catheter (CVC) insertion and its duration of use. Therefore, to reduce the incidence of CVD, catheterization in the central vein (CV) should be minimized, along with its duration of use. In this review, we will first explain the basic territories of the CV and introduce its pathophysiology, clinical features, and advanced treatment options. Finally, we will emphasize prevention of CVD.

show abstract

Usefulness of assisted procedures for arteriovenous fistula maturation without compromising access patency

Abstract: Our results support that idea that assisted maturation procedures can ensure the success of immature AVF without compromising long-term patency. These procedures can be considered more positively for increasing AVF use for VA placement in HD patients.

Cited by 11 publications

References 20 publications

Endovascular management in immature arteriovenous fistula for hemodialysis

Endovascular management in immature arteriovenous fistula for hemodialysis

Patency with antiplatelet treatment after vascular access intervention therapy: a retrospective observational study

Central venous disease in hemodialysis patients

Contact Info

Product

Resources

About